Prior to joining Oxford Biomarker Services in September 2004, Dr Barnes spent 9 years working as an IT consultant for a software services company specialising in providing IT services to the science and engineering industries. This role included systems analysis and implementation, application development, database administration, project management and line management. Martin has been involved in all areas of the IT project lifecycle - from initial requirements, analysis and feasibility studies through to roll-out and subsequent support.

Martin has also been involved in IT process improvement and has written and presented training courses. This work included five and a half years in the pharmaceutical industry, three and a half years of which were at Oxford GlycoSciences as a consultant for up to 40 other IT staff.

Since gaining his PhD, Dr Bell has developed and applied mass spectrometric methods to drug discovery and development processes. He has experience of a wide range of instrumentation, particularly LC/MS/MS & applications in the pharmaceutical industry. He was involved in biomarker discovery and target identification using both gel and label-free proteomics. After 18 years with GlaxoSmithKline, he joined the company in November 2006.

David has over co-authored over 20 publications on the utilisation of mass spectrometry in pharma R&D and recently presented at the 17th International Mass Spectrometry Conference in Prague.

James joined the company in October 2009, having spent 10 years as an assay development scientist specialising in ligand binding assays for measuring biomarkers, pharmacokinetics, immunogenicity and vaccine potency on a wide range of manual and automated platforms. He has experience of setting up and working in GLP and GCP laboratories including laboratory validation and management of regulatory analytical projects. James has previously worked at R&D Systems, Covance Laboratories, Emergent Biosolutions and Veeda Laboratories.